Scott Biggs and Douglas M. Long of IQVIA delivered a keynote on 2024-2025 healthcare and pharmaceutical trends, highlighting drug shortages, pharmacy closures, and the United States dependence on ...
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...
Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...
Juan Carlos Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), and Marissa Schlaifer, RPh, ...
The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...
None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...
Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Co-presenter, Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, discussed this topic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback